Managing Papulopustular Rosacea With Once-daily ORACEA® (doxycycline, USP) 40 mg* Capsules

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Understanding the Burden of Rosacea

      Management Approach and Goals of Therapy

      ORACEA® (doxycycline, USP) 40 mg* Capsules:
      Efficacy and Tolerability vs Placebo

      Results From a Clinical Study: ORACEA®
      (doxycycline, USP) 40 mg Capsules vs Doxycycline 100 mg

      Antibiotic Stewardship With ORACEA®
      (doxycycline, USP) 40 mg* Capsules

      Indication and Important
      Safety Information

      See full Prescribing Information Click Here

      Important Safety Information and Indication

      Indication: ORACEA® (doxycycline, USP) 40 mg* Capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. Warnings/Precautions: ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established.

      You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

      *30 mg immediate release & 10 mg delayed release beads

      Meet the Speakers

      Hilary E. Baldwin, MD, FAAD headshot

      Hilary E. Baldwin, MD, FAAD

      Medical Director
      Acne Treatment & Research Center
      Brooklyn, NY

      Clinical Associate Professor
      Rutgers Robert Wood Johnson Medical Center
      New Brunswick, NJ


      Jeffrey S. Fromowitz, MD, FAAD

      Jeffrey S. Fromowitz, MD, FAAD

      Managing Partner and Medical Director
      Boca Raton, FL

      Adjunct Assistant Professor of Medicine
      Florida Atlantic University College of Medicine
      Boca Raton, FL

      The production of this Dermatology Times® video was supported by Galderma Laboratories, L.P. The speakers are paid
      consultants of Galderma Laboratories, L.P.

      © 2020 Galderma Laboratories, L.P. United States, All Rights Reserved. All trademarks are the property of their respective
      owners.

      USMP/ORA/0037/0820f